US major Johnson & Johnson MedTech has announced that its Dual Energy THERMOCOOL SMARTTOUCH SF Catheter has obtained the European CE mark for the treatment of cardiac arrhythmias. This approval is a significant milestone in the expansion of the company’s electrophysiology portfolio, offering a new treatment option for patients suffering from cardiac arrhythmias.
Product Overview
The Dual Energy THERMOCOOL SMARTTOUCH SF Catheter is an irrigated, contact-force sensing catheter powered by the TRUPULSE Generator. It is fully integrated with the CARTO 3 System for electro-anatomical mapping and tag indexing. The product’s compatibility with TRUPULSE Generator hardware is expected in the first half of 2025. Once fully approved, the catheter will have the ability to switch between radiofrequency (RF) and pulsed field (PF) energy, providing clinicians with a versatile tool for treating complex cardiac arrhythmias.
Clinical and Market Impact
The CE mark approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter is a testament to Johnson & Johnson MedTech’s commitment to innovation in electrophysiology. This dual-energy capability represents a significant advancement in the treatment of cardiac arrhythmias, offering improved procedural outcomes and patient care. The integration with the CARTO 3 System and the upcoming compatibility with the TRUPULSE Generator further enhance the catheter’s utility in clinical settings, positioning it as a leading solution in the field.
Future Prospects
With the CE mark approval, Johnson & Johnson MedTech is well-positioned to expand the use of the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter in European markets. The ability to switch between RF and PF energy in the same catheter provides clinicians with greater flexibility and control during procedures, potentially improving the treatment of a wide range of cardiac arrhythmias. This approval is expected to drive further adoption of the technology and enhance Johnson & Johnson MedTech’s market presence in the electrophysiology space.
